Biology and Soft Matter Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA.
Biology and Soft Matter Division, Oak Ridge National Laboratory, Oak Ridge, TN 37831, USA.
Structure. 2018 Mar 6;26(3):383-390.e3. doi: 10.1016/j.str.2018.01.006. Epub 2018 Feb 8.
Human carbonic anhydrases (hCAs) play various roles in cells, and have been drug targets for decades. Sequence similarities of hCA isoforms necessitate designing specific inhibitors, which requires detailed structural information for hCA-inhibitor complexes. We present room temperature neutron structures of hCA II in complex with three clinical drugs that provide in-depth analysis of drug binding, including protonation states of the inhibitors, hydration water structure, and direct visualization of hydrogen-bonding networks in the enzyme's active site. All sulfonamide inhibitors studied bind to the Zn metal center in the deprotonated, anionic, form. Other chemical groups of the drugs can remain neutral or be protonated when bound to hCA II. MD simulations have shown that flexible functional groups of the inhibitors may alter their conformations at room temperature and occupy different sub-sites. This study offers insights into the design of specific drugs to target cancer-related hCA isoform IX.
人碳酸酐酶(hCA)在细胞中发挥多种作用,并且数十年来一直是药物靶点。hCA 同工型的序列相似性需要设计特定的抑制剂,这需要 hCA-抑制剂复合物的详细结构信息。我们呈现了 hCA II 与三种临床药物形成复合物的室温中子结构,对药物结合进行了深入分析,包括抑制剂的质子化状态、水合结构以及酶活性部位氢键网络的直接可视化。研究中所有的磺胺类抑制剂都以去质子化、阴离子形式结合到 Zn 金属中心。当与 hCA II 结合时,药物的其他化学基团可以保持中性或质子化。MD 模拟表明,抑制剂的柔性功能基团可能会在室温下改变它们的构象,并占据不同的亚位。这项研究为设计针对与癌症相关的 hCA 同工型 IX 的特异性药物提供了思路。